Allan S. Brett
Abstract
In January 2009, the FDA approved milnacipran (Savella), a selective serotonin and norepinephrine reuptake inhibitor, for treatment of fibromyalgia. In an industry-sponsored randomized trial, 1025 U.S. and Canadian patients with fibromyalgia (mean duration of symptoms, 11 years) received milnacipran or placebo. Dosing started at 12.5 mg once daily and was titrated to …
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In January 2009, the FDA approved milnacipran (Savella), a selective serotonin and norepinephrine reuptake inhibitor, for treatment of fibromyalgia. In an industry-sponsored randomized trial, 1025 U.S. and Canadian patients with fibromyalgia (mean duration of symptoms, 11 years) received milnacipran or placebo. Dosing started at 12.5 mg once daily and was titrated to …
Key concepts: Milnacipran, Fibromyalgia, Medicine, Placebo, Dosing, Randomized controlled trial, Reuptake inhibitor, Anesthesia